...BRAF mutations are poor prognostic indicators for colon adenocarcinoma (COAD). Although the prevalence of BRAF-mutated C...
...BRAF V600E is the most frequent pathogenic variant of ATC. Dabrafenib and Trametinib (D+T) have shown promising efficacy...
...BRAFV600 mutation, inhibitors of BRAF and MEK have improved survival. Resistance may be acquired through late genetic al...
...BRAF, EGFR, ERBB2, KIT, and KRAS). The results demonstrate good F1-scores for both LLMs-averaging 64% for GPT-4.0 and 70...
...BRAF mutations, specifically p.G469A and p.D594N. The link between the presence of eosinophilic cells and BRAF mutation ...
...BRAF wild-type. At 24 months post-treatment, the patient remains disease-free with no evidence of recurrence or metastas...
Treatment based on BRAF/MEK kinase inhibitors is one of the most commonly used methods in advanced melanoma therapy, but...
...BRAF (18.3%), and KIT (9.0%) were the most common mutations. CDKN2A and CDKN2B deletions occurred in over 20% of the sam...
...BRAF inhibitor. Using primary and established BRAFV600E CRC cells, we show that the development of resistance to PLX8394...
...BRAF wild type (WT) status. However, its efficacy compared to standard of care (SoC) in randomized controlled trials (RC...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
